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There is evidence supporting a role for the nociceptin/orphanin FQ (N/OFQ; NOP) receptor and its endogenous ligand N/OFQ in
the modulation of neurogenic inflammation, airway tone and calibre. We hypothesized that NOP receptor activation has bene-
ficial effects upon asthma immunopathology and airway hyperresponsiveness. Therefore, the expression and function of N/OFQ
and the NOP receptor were examined in healthy and asthmatic human airway tissues. The concept was further addressed in an
animal model of allergic asthma.
EXPERIMENTAL APPROACH
NOP receptor expression was investigated by quantitative real-time PCR. Sputum N/OFQ was determined by RIA. N/OFQ func-
tion was tested using several assays including proliferation, migration, collagen gel contraction and wound healing. The effects of
N/OFQ administration in vivo were studied in ovalbumin (OVA)-sensitized and challenged mice.
KEY RESULTS
NOP receptors were expressed on a wide range of human and mouse immune and airway cells. Eosinophils expressed N/OFQ-
precursor mRNA and their number correlated with N/OFQ concentration. N/OFQ was found in human sputum and increased in
asthma. Additionally, in asthmatic human lungs N/OFQ immunoreactivity was elevated. NOP receptor activation inhibited
migration of immunocytes and increased wound healing in airway structural cells. Furthermore, N/OFQ relaxed spasmogen-
stimulated gel contraction. Remarkably, these findings were mirrored in OVA-mice where N/OFQ treatment before or during
sensitization substantially reduced airway constriction and immunocyte trafficking to the lung, in particular eosinophils. N/OFQ
also reduced inflammatory mediators and mucin production.
CONCLUSIONS AND IMPLICATIONS
We demonstrated a novel dual airway immunomodulator/bronchodilator role for N/OFQ and suggest targeting this system as an
innovative treatment for asthma.
N/OFQ-NOP system modulates airway immune response BJPAbbreviations
AHR, airway hyperresponsiveness; ECM, epithelial conditioned media; EFS, electrical field stimulation; EOL-1, eosinophil-
like cell line; GINA, Global Initiative for Asthma; HASM, human airway smoothmuscle; HBEC, human bronchial epithelial
cells; HLMC, human lung mast cells; HMC-1, human mastocytoma cell line; NOP receptor, N/OFQ peptide receptor; N/
OFQ, nociceptin/orphanin FQ; OVA, ovalbumin; PBEs, peripheral blood eosinophils; ppN/OFQ, prepronociceptin; SCF,




ACh CCL26 IL-5 IL-13 TNF-α
Bradykinin CXCL10 IL-8 (CXCL8) IL-17 UFP-101
Carbachol IFN-γ IL-10 N/OFQ
CCL11 IL-4 IL-12 Stem cell factor
These Tables list key protein targets and ligands in this article which are hyperlinked to corresponding entries in http://www.guidetopharmacology.org,
the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Pawson et al., 2014) and are permanently archived in the Concise Guide
to PHARMACOLOGY 2015/16 (Alexander et al., 2015).Introduction
Nociceptin/orphanin FQ (N/OFQ) is the endogenous peptide
activator of the N/OFQ receptor (NOP receptor), classified by
The International Union of Basic and Clinical Pharmacology
(IUPHAR) as a non-opioid (or non-classical) member of the
opioid family. Since the discovery of the NOP receptor and
its deorphanization, the N/OFQ-NOP receptor system has re-
vealed some intriguing pharmacology. Not least a dual action
in pain processing with anti-opioid actions supraspinally and
antinociceptive actions in the spinal cord (Halford et al.,
1995; Lambert, 2008). The vast range of additional peripheral
actions for NOP receptor activation have also reinvigorated
interest regarding its immunomodulatory actions and effects
on isolated airway tissues.
The increasing prevalence of asthma is a major health prob-
lem affecting 235 million worldwide with an annual mortality
of ~0.25 million (WHO, 2013). Asthma is a complex heteroge-
neous and devastating disease characterized by variable degree
of airflow obstruction, airway hyperresponsiveness, chronic
airway inflammation and airway remodelling (Brightling et al.,
2012). These changes are the result of a crosstalk between
resident structural airway smooth muscle and epithelial cells,
progenitors including fibrocytes, infiltrating airway submucosal
inflammatory cells (eosinophils and T-cells) (Brightling et al.,
2002a), localized mast cells within airway smooth muscle
bundles (Brightling et al., 2002a) and Th2 cells (and their
cytokines) (Brightling et al., 2002b).
With respect to airways, NOP receptor activation abolishes
capsaicin- and electrical field stimulation (EFS)-induced contrac-
tion in guinea pig airways (Shah et al., 1998; Corboz et al., 2000)
and EFS-induced contractions of an ex vivo human bronchial
ring preparation (Basso et al., 2005). These effects have been
attributed to inhibition of airway ACh and sensory neuropep-
tide release (Patel et al., 1997; Corboz et al., 2000). In ovalbumin
(OVA)-sensitized mice, capsaicin induces increased airway
hyperresponsiveness (AHR) that may be partly mediated by
reduced endogenous N/OFQ. More significantly, N/OFQinhibits capsaicin-induced bronchoconstriction in both naïve
and OVA-sensitized mice (D’Agostino et al., 2010). In addition,
NOP receptor agonists are antitussive in preclinical models
(McLeod et al., 2001).
In a clinical setting, combined anti-inflammatory/broncho-
dilator therapy is effective in controlling asthma; however,
~10% of asthmatics display variable steroid-resistant patterns
of inflammation (Bousquet et al., 2009). The development of
new therapies combining both bronchodilator and steroid-free
immunosuppressive profiles offer several advantages over the
current treatments not least a simplified dosing regimen.
We hypothesized that the N/OFQ-NOP receptor system
plays a critical role in the pathogenesis of airway inflammation,
airflow obstruction and hyperresponsiveness, the hallmarks of
asthma. There are currently no data on N/OFQ-NOP receptor
expression in cells from human airways, and as such, its poten-
tial role in human asthma is unknown. We have addressed this
hypothesis by investigating NOP receptor, prepronociceptin
(ppN/OFQ)mRNA andN/OFQ peptide expression and function
within airway tissue. We have used ex vivo human tissue from
phenotyped asthmatic and non-asthmatic patients and volun-
teers and compared data with an established in vivo OVA-
sensitized mouse model of asthma. We showed that N/OFQ is
a candidate dual immunomodulator and bronchodilator.Methods
Detailed methods are available in the Supporting Information.
Subjects
Asthmatic subjects and healthy controls were recruited in
Leicester, UK, and their clinical characteristic are reported
in Table 1 with the approval of the Leicestershire Ethics
Committees. All patients gave written informed consent.
Asthmatic subjects had a consistent history and objective
evidence of asthma. Asthma severity was defined by Global
Initiative for Asthma (GINA) treatment steps (mild–moderateBritish Journal of Pharmacology (2016) 173 1286–1301 1287
Table 1
Clinical characteristics of healthy and asthmatic volunteers recruited for sputum analysis.
Healthy (n = 29) GINA 1–3 (n = 30) GINA 4–5 (n = 55) P value
Age in years# 50 ± 3 55 ± 2 56 ± 2 0.48
Male, n (%) 19 (66) 20 (67) 39 (58) 0.85
Smoking, n (%) 9 (31) 12 (40) 16 (29) 0.99
Current 2 (22) 2 (17) 3 (19)
Ex 7 (78) 10 (83) 13 (81)
Smoking (pack years)# 3.9 ± 1.5 6.3 ± 1.9 4.5 ± 1.2 0.60
FEV1% predicted
# 105.3 ± 3.6 84.2 ± 4.1 69.3 ± 3.3 <0.001
FEV1/FVC%
# 78.5 ± 1.2 71.3 ± 2.1 34.5 ± 4.5 <0.001
Sputum neutrophils, %* 50 (31–61.5) 62.4 (55–78.5) 56.3 (49–69) 0.03
Sputum macrophages, %* 39.3(32.5–60.8) 23.8(14.3–36.5) 19.9 (14–28) <0.001
Sputum eosinophils, %* 1.8 ± 0.6 (0–5) 0.8 (0.5–1.8) 2.9 (1.8–6.9) <0.001
Sputum epithelial cells, %* 2.0 (1.0–3.3) 1.0 (0.8–2.3) 2.5 (1.8–4.0) 0.03
Sputum lymphocytes, %* 0.3 (0–0.3) 0.0 (0.0–0.3) 0.3 (0.0–0.5) 0.25
P value represents comparisons between healthy subjects and GINA 4–5 patients.
#Mean ± SEM;
*Median (interquartile range).
BJP S R Singh et al.GINA 1–3 and severe GINA 4–5). Subjects underwent exten-
sive clinical characterization including sputum induction
and video-assisted fibreoptic bronchoscopic examination.
Cell isolation and culture
Pure human airway smoothmuscle (HASM) bundles (Brightling
et al., 2005), primary human bronchial epithelial cells (HBEC)
(Martin et al., 2011) and human lung mast cells (HLMC)
(Sanmugalingam et al., 2000) were isolated and cultured as
described. Human mastocytoma (HMC-1) and human
eosinophil-like (EOL-1) cell lines were cultured, as described
previously (Butterfield et al., 1990). Peripheral blood eosinophils
(PBEs) were isolated from heparin-treated peripheral venous
blood from healthy control subjects and asthmatic volunteers
using LS columns (Miltenyi Biotec, UK).
Membrane preparation and 125I radioisotope
dilution assay
Membranes were prepared from freshly harvested cells, HASM
(asthmatic and non-asthmatic) and HMC-1 cells at confluence.
Cells were suspended in homogenizing buffer of Tris–HCl
(50 mM), MgSO4 (5 mM) pH 7.4 with KOH and were homoge-
nized followed by centrifugation at 4890 g for 10 min at 4°C.
Membrane protein (20 μg of CHOhNOP, 200 μg of HASM and
HMC-1) was incubated in 0.5 mL of homogenization buffer
containing 0.5% BSA, 10 μM peptidase inhibitors (amastatin,
bestatin, captopril and phosphoramidon, Sigma-Aldrich, Poole,
UK) and various concentrations of [125I]-N/OFQ (~10 pM–1 nM,
Perkin Elmer, UK) for 1 h at room temperature. Non-specific
binding was defined in the presence of 1 μM unlabelled
N/OFQ. Bound and free radioactivities were separated by vac-
uum filtration using a Brandel cell harvester onto Whatman
GF/B filters (Fisher Scientific, Loughborough, UK). Filter-bound
radioactivity was assessed by a γ counter, and receptor density
was calculated from dilution isotherms.1288 British Journal of Pharmacology (2016) 173 1286–1301Quantitative real-time PCR
All airway and immune cells from volunteers and patients or
cultured cells were prepared immediately or stored in
RNAlater® (Ambion, Warrington, UK) before RNA extraction.
Total RNA was extracted, and final RNA pellets (patient or cul-
tured cells) were resuspended in PCR-grade water. The mass of
RNA was determined using an Eppendorf Biophotometer
(Fisher Scientific, Loughborough, UK) and RNA purity
crudely assessed from the 260/280 nm ratio, which was in
the range of 1.9 to 2.1 for all samples using a nanodrop
(Thermo Scientific, UK). Total RNA extracted was processed
using Turbo DNA-free® kit and a High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, Warrington,
UK) according to the manufacturer’s instructions. Quantitative
RT-PCR assessed mRNA quantity using commercially available
TaqMan® gene expression assays from Applied Biosystems for
the human NOP receptor (Hs00173471_m1), human ppN/OFQ
or ppNOC (Hs00173823_m1), human CCL11 (eotaxin-1;
Hs00237013_m1), human CCL26 (eotaxin-3; Hs00171146_m1)
and GAPDH or β2 microglobulin. TaqMan probes for the genes
under investigation and GAPDH contained different dyes and
so were used in a duplex assay format. The thermal profile for
quantitative real-time PCR reactions in the StepOne instrument
(Applied Biosystems) was 2 min at 50°C, 10 min at 95°C, 40 or
50 cycles of 15 s at 95°C and 1 min at 60°C. Non-template
controls were included for all samples. Results are expressed as
ΔCt: the difference in cycle threshold of the gene of interest
and the housekeeper gene, GAPDHor β2microglobulin. Typical
methodology is further described in Leonard et al. (2009).
Immunohistochemistry
Sequential 2 μm sections were cut from glycomethacrylate-
embedded asthmatic andhealthy bronchial biopsies and stained
using a polyclonal anti-human N/OFQ antibody (1 in 200 dilu-
tion, Phoenix EuropeGmbH,Germany) and appropriate isotype
N/OFQ-NOP system modulates airway immune response BJPcontrol rabbit IgG (Phoenix Europe GmbH). N/OFQ staining in
airway smooth muscle was assessed using a semi-quantitative
score of no staining = 0, very low = 1, low = 2,moderate = 3, high
= 4 and very high = 5.
Cell migration
The 24-well or 96-well Transwell migration assay was used to
measure the migration of HMC-1 cells, HLMCs, EOL-1 cells
and PBEs in response to chemoattractants. To investigate mast
cell migration, 450 μL of stem cell factor (SCF) (10 ng·mL1,
R&D Systems, Abingdon, UK), CXCL10 (10 ng·mL1, R&D
Systems, Abingdon, UK) and HASM supernatants stimulated
with recombinant TNF-α for 24 h (10 ng·mL1, R&D Systems,
Abingdon, UK) were used as chemoattractants. We used
epithelial conditioned media (ECM) and sputum from severe
asthmatic volunteers (with very high levels of N/OFQ) as
chemoattractants to study PBE and EOL-1 cell migration.
Chemoattractants were added to the bottom compartment of
each well, with the exception of the negative controls. Cells
were then added to the top chamber of each well (2.5 × 105
HMC-1 cells; 1 × 105 HLMCs; 2.5 × 104 eosinophils and EOL-1
cells). N/OFQ was added to the top compartment. To allow
migration, mast cells (HMC-1 and HLMCs) were incubated for
4 h at 37°C and EOL-1 cells, eosinophils were incubated for
90 min at 37°C. Following this, cells present in the lower well
were recovered and then counted on a flow cytometer or
resuspended in trypan blue (0.4%) stain for counting with a
haemocytometer by a blinded observer (Kaur et al., 2006).
Measurement of CCL11 and CCL26 by ELISA
HASM cells or undifferentiated HBECs (both 1 × 105 cells per
well) were grown to confluency in a six-well culture plate.
Cells were then serum starved for 24 h and pre-incubated
with 300 nM of N/OFQ for 60 min at 37°C in the presence
of peptidase inhibitors. Next, HASM cells were stimulated in
the presence or absence of TNF-α (10 ng·mL1, R&D Systems,
Abingdon, UK) and HBEC in the presence or absence of IL-13
(10 ng·mL1, R&D Systems, Abingdon, UK) for 24 h at 37°C.
After 24 h, supernatants were collected, spun down to remove
debris and stored at 80°C till further analysis. Colorimetric
human CCL11 and CCL26 ELISAs (R&D Systems, Minneapolis,
MN, USA) were performed according to the manufacturer’s
protocol.
Measurement of IL-8 release from HMC-1 cells
HMC-1 cells were grown in six-well culture plates and then pre-
incubated in the presence or absence of N/OFQ (300 nM)
for 60 min at 37°C in the presence of peptidase inhibitors.
Next, cells were stimulated in the presence or absence of
SCF (10 ng·mL1, R&D Systems, Abingdon, UK) for 24 h
at 37°C. After 24 h, supernatants were collected, centrifuged
at 2000 g for 5 min to remove debris and stored at 80°C till
further analysis. IL-8 concentrations were determined using a
DuoSet ELISA Development Kit from R&D Systems.
Wound healing
Non-asthmatic and asthmatic HBEC cells were seeded onto
eight-well culture plates, serum deprived for 24 h and then
wounded using a sterile 200 μL pipette tip in a predeterminedgrid pattern. After beingwounded, cells were washed and treated
in the presence or absence of N/OFQ (3 and 300 nM). Non-
asthmatic and asthmaticHASMcells were seeded onto eight-well
fibronectin-coated plates, serum deprived for 24 h in ITS me-
dium, and then wounded using a sterile 200 μL pipette tip in a
predetermined grid pattern. After being wounded, HASM cells
were washed and treated in the presence or absence of N/OFQ
(3, 30 and 300 nM). Wounds were then photographed at base-
line, after 6 and 24 h. Wound areas were analysed by a blinded
observer using IMAGEJ software, and the extent of repair was
calculated and expressed as a percentage of wound healed area.Sputum N/OFQ measurement by RIA
Acidified sputum samples were extracted using Strata C18-E
solid-phase extraction cartridges with eluate. N/OFQ was
measured by RIA as described previously (Williams et al., 2008).Assessment of airway smooth muscle
contraction by collagen gel analysis
Contractile properties of airway smoothmuscle cells were assessed
using a collagen gel contraction assay. Collagen gelswere impreg-
nated with HASM cells (2.5 × 105 cells) resuspended in DMEM
with GlutaMAX-1 supplemented with penicillin (100 U·mL1),
streptomycin (100 μg·mL1), amphotericin (0.25 μg·mL1),
non-essential amino acids (100 μM) (Invitrogen, Paisley, United
Kingdom), sodium pyruvate (1 mM) and insulin-transferrin-
selenium (1%) (Sigma-Aldrich). Next, 450 μL of gel mixture was
added to each well of a PBS 2% BSA pre-coated 24-well plate
and allowed to polymerize at 37°C for 90min. After polymeriza-
tion, 500 μL DMEMwith GlutaMAX-1 (supplemented as above)
was added to eachwell, and the gelwas detached from the plastic
surface to allow free contraction. Collagen gels were then
incubated in the presence or absence of N/OFQ (3 and
300 nM) for 24 h at 37°C. Carbachol (100 μM) or bradykinin
(10 nM) were then added to each well in an equal volume of
the above media. The collagen gels were photographed at spec-
ified time points over a 3 h period by a blinded observer, and the
gel size was calculated at specific time points, as a percentage of
the well area, using IMAGEJ software (National Institutes of
Health, USA). All gel conditions were performed in duplicate.
Animal studies
Animal studies reported are in compliance with the ARRIVE
guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015).
The investigation was approved by the Veterinary Animal
Care and Use Committee of the Second University of Naples
(1966/7.17.2012) and conforms to the National Ethical
Guidelines of the Italian Ministry of Health and the Guide
for the Care and Use of Laboratory Animals (National Insti-
tute of Health, Bethesda, MD,USA, revised 1996). All experi-
mental procedures were in accordance with Italian DLgs
26/2014, application of the EU Directive 2010/63/EU.
BALB/c mice were obtained from Harlan Laboratory (Udine,
Italy). Mice were housed in the animal facility of the Second
University of Naples in standard conditions. Food and water
were supplied ad libitum. Room temperature was 22°C–24°C,
relative humidity was 40%–50%, and the day/night cycle
was set at 12 h/12 h. Mice were acclimatized for 1 week before
starting any procedures in 5 mice per cage.British Journal of Pharmacology (2016) 173 1286–1301 1289
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Female BALB/cmice were used in this study. Animals were sensi-
tized toOVAby s.c. injectionwith 0.4mLof 10μgOVA, absorbed
to 3.3 mg of aluminium hydroxide gel in sterile saline at days 0
and 7. From day 21 to 23, all OVA-sensitized mice were aerosol
challenged (7-min-long daily sessions) with 1% OVA in PBS
using an ultrasonic nebulizer (De Vilbiss Health Care, UK Ltd.,
Heston, Middlesex, UK).We used untreated animals (naïvemice)
and OVA-sensitized mice, treated with 100 μL of saline solution
(vehicle) or 100 μL of N/OFQ (15 μg·kg1). Two different experi-
mental protocols were used for N/OFQ treatment. In the first
protocol (post-OVA sensitization), vehicle or N/OFQ were admi-
nistered i.p. from day 21 to 23, 30 min before each OVA aerosol
challenge (Figure 2A), while in the second protocol (pre-OVA
sensitization), vehicle or N/OFQ were administered i.p., at day 0
and 7, 30 min before each allergen injection (Figure 2B).
Twenty-four hours after the last aerosol challenge, animals were
killed, and bronchopulmonary function, pulmonary tissue and
bronchoalveolar lavage (BAL) fluid collection were performed.
Airway hyperresponsiveness. AHR to ACh was assessed in an
isolated and perfused mouse lung model as described in detail
in Roviezzo et al. (2007). Mice were anaesthetized with
ketamine HCl 40 mg kg-1 i.p. and medetomidine hydrochloride
0.15 mg kg-1 i.p and were exanguinated after incision of the
renal vein as the method required. After 60 min, mean tidal
volume was 0.21 ± 0.02 mL (n = 61), mean airway resistance
0.23 ± 0.08 cmH2Os·mL
1 and mean pulmonary artery pressure
2.9 ± 1.4 cmH2O. The airway resistance measured was corrected
for the resistance of the pneumotachograph and the tracheal
cannula of 0.6 cmH2Os·mL
1.
Bronchoalveolar lavage. Micewere anaesthetizedwith ketamine
HCl 40 mg kg-1 i.p. and medetomidine hydrochloride 0.15
mgkg-1 i.p and then killed by cervical dislocation. Mouse BAL
fluid was collected as follows: 1.5 mL of saline was instilled
and withdrawn from the lungs via an intratracheal cannula;
this lavage was performed three times, and different samples
were collected. BAL fluid was centrifuged at 1000× g for
10 min at 4°C. The supernatant was transferred into tubes and
stored at 70°C before use to analyse the cytokine production.
Cell pellets were resuspended in PBS to a final volume of
0.5 mL for total and differential cell counting.
Total and differential cell count. Total cell count was performed
using the Countess automated cell counter (Invitrogen), which
evaluates cell number and viability using trypan blue stain
according to the manufacturer’s instructions. Differential
counting was performed on Diff-Quik (Reagena, Gentaur,
Italy) stained cytospins. At least 200 cells were counted on
each cytospin according to standard morphological criteria
under light microscopy.
Cytokine assays. Measurement of cytokines in BAL fluid was
performed taking advantage of the well-established Luminex
xMAP technology that allows measurement of a panel of
analytes in a small sample volume (100 μL) simultaneously.
The assays were performed using a Milliplex Cytokine Panel
plate (Millipore-Merck, Vimodrone-Milan, Italy) according
to the manufacturer’s instructions on an automated1290 British Journal of Pharmacology (2016) 173 1286–1301immunoassay analyser (Luminex® 200™ System, Invitrogen,
Milan, Italy) as detailed previously (Vignali, 2000). All samples
were run in duplicate. Data were analysed using XPONENT
software (1.9 version, Luminex® 200™ System, Invitrogen).
Histochemistry and immunofluorescence. Lungs were perfused and
fixed in 10% phosphate-buffered formalin. Tissue was embedded
in paraffin and cut in 5 μm sections for histological analysis. For
immunofluorescence, after deparaffinization and rehydration,
tissue sections were treated with 10% normal donkey serum for
30 min at room temperature and then incubated with the
primary antibodies diluted in PBS. After being washed several
times with PBS, the sections were incubated with the FITC-
conjugated and tetramethyl rhodamine isothiocyanate-
conjugated secondary antibodies (Jackson ImmunoResearch).
Nuclei were stained with DAPI. For the assessment of
inflammation, sections were stained with haematoxylin–eosin
(HE). To facilitate the recognition of eosinophils, a modified HE
protocol was used (Meyerholz et al., 2009). The number of
eosinophils mm-2 of the peribronchial tissue was measured. The
number of mast cells mm-2 of the lung tissue was measured after
staining with toluidine blue. Mucin production was assessed by
immunolabelling with anti-mucin 5 AC antibody (Abcam,
Cambridge Science Park, UK). Mucin-positive cells were
quantified in the epithelial layer of the bronchi by counting
labelled cells per total number of cells within the airway
epithelium. N/OFQ expression within the mouse airways was
investigated by immunolabelling with anti-N/OFQ antibody
(Novus Biologicals, Italy). All samples were analysed with a Leica
fluorescence microscope (Leica Microsystems GmbH, Wetzlar,
Germany) and a Zeiss LSM 700 confocal microscope (Carl Zeiss
Microscopy GmbH, Jena, Germany). The values of corrected
total fluorescence of N/OFQ per unit area of a peribronchial
tissue from control (n = 3) and OVA mice (n = 3) were obtained
using IMAGEJ software (imagej.nih.gov), adapted from Burgess
et al. (2010).
Measurement of OVA-specific IgE and IgG levels in BAL fluid by
ELISA. Briefly, BAL fluid samples were mixed with an equal
volume of trifluoroacetic acid (TFA: 1% v : v). Acidified
samples were then loaded onto Strata C18-E solid-phase
extraction cartridges and washed twice with 0.1% TFA.
Samples were eluted with 0.1% TFA 3 mL 60% acetonitrile,
lyophilized using a centrifugal evaporator and then freeze
dried. Before assay, the sample was reconstituted in assay
buffer. OVA-specific IgE (Cambridge Bioscience, UK; assay
range 20.7 pg·mL1–20 ng·mL1) and OVA-specific IgG (2B
Scientific, Oxford, UK, assay range 1.56–100 U·mL1) ELISA
was performed according to the manufacturer’s protocol.
Statistical analysis
Analysis between groups was performed (PRISM Version 6
(GraphPad, CA, USA)) by paired or unpaired t-tests and across
groups by one-way/two-way ANOVA with appropriate post hoc
comparisons. Post hoc tests were only performed if Fwas signifi-
cant. Due to the limitations in the availability of tissuematerial,
some animal and human studies were performed with n < 5.
However, no statistical analysis was performed for sample sizes
less than 5. For sputum N/OFQ measurements, subjects were
categorized into three groups: healthy, mild/moderate asth-
matics (GINA 1–3) and severe asthmatics (GINA 4–5). Between
N/OFQ-NOP system modulates airway immune response BJPgroup differences were analysed by unpaired t-tests or Fisher’s
exact test. Correlations were assessed by Spearman rank (rs)
coefficients. Values of P < 0.05 were considered significant.Results
N/OFQ expression in asthmatic human
airways and blood eosinophils
Severe asthmatics (GINA 4–5) had significantly higher levels of
N/OFQ in sputum relative to healthy volunteers and GINA
1–3 subjects (Figure 1A). There was no statistical difference
between levels of N/OFQ in the sputum from healthy and
asthmatic subjects (mild–moderate). Although N/OFQ and
FEV1/FVC did not correlate (Supporting Information Fig. SE1),Figure 1
Endogenous N/OFQ expression is increased in human asthmatic airways; th
levels from healthy (n = 29 subjects; n = 5 below detection limit), mild to m
limit) and severe asthmatic (GINA 4–5; n = 55 patients; n = 2 below detecti
and sputum eosinophils (%) in asthmatics (mild–moderate and severe); (C)
age, n = 3 healthy donors and n = 6 asthmatic donors), scale bars 100 μm; (D
tissue); (E) quantitative real-time PCR demonstrating ppN/OFQ mRNA exp
quantitative real-time PCR demonstrating NOP receptor mRNA expression
cells from individual donors for HASM, HBEC, HLMC and PBEs and independ
as mean ± SEM. Comparisons made by unpaired t-test or one-way ANOVA fowe observed a weak correlation between the increased number
of eosinophils in asthmatic patients (mild–moderate and severe)
and sputum N/OFQ (Figure 1B, Table 1). In a search for the
source of N/OFQ peptide, we assessed its expression in human
airway tissue using IHC. N/OFQ staining appeared to be
increased in asthma biopsies with a preferential sub-epithelial
and extracellular matrix location and a weak staining in HASM
bundles (Figure 1C and D). These observations are consistent
with sputum measurements and indicate that the eosinophils
potentially release N/OFQ within the airways. In fact,
ppN/OFQmRNA transcripts were found in PBEs, but not in hu-
man airway structural cells, from healthy (expression observed
in 5/9 independent samples; ΔCт = 21.73 ± 1.57) and
asthmatic (expression observed in 5/7 independent samples;
ΔCт = 18.31 ± 2.66) patients with no statistically significant
differences (P < 0.05; Figure 1E).e NOP receptor is expressed in human airways. (A) Sputum N/OFQ
oderate asthmatic (GINA 1–3; n = 30 patients; n = 7 below detection
on limit) donors; (B) correlation between sputum N/OFQ (pg·mL1)
IHC staining of human airway tissues for N/OFQ (representative im-
) semi-quantitative IHC staining score (n<5 for healthy human airway
ression on PBEs (n = 5 healthy and n = 5 asthmatic donors); and (F)
in human airway structural and immune cells (n numbers represent
ent experiments for HMC-1 and EOL-1 cell lines). Data are expressed
llowed by appropriate post hoc tests where relevant. *P <0.05.
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BJP S R Singh et al.NOP receptor expression on HLMCs, HMC-1
and airway structural cells
Interestingly, HLMCs and HMC-1 cells expressed higher levels
of NOP receptor mRNA transcript than HASM cells and HBECs.
NOP receptor mRNA transcript was also detected in EOL-1 cells
and native eosinophils isolated from the peripheral blood of
healthy and asthmatic volunteers. In contrast to N/OFQ, no
differences were observed between healthy and asthmatic sub-
jects documenting no disease signal (Figure 1F). Additionally,
in a series of [125I]-N/OFQ radioligand isotope dilution assays,
cell membrane NOP receptor density was quantified on HASM
(Bmax; 7.3 ± 1.1 fmol·mg
1 protein, n = 9) and HMC-1 cells
(Bmax; 17 ± 5.9 fmol·mg
1 protein, n = 3). NOP receptor density
was significantly increased in HMC-1 cells compared with
HASM (P < 0.05; unpaired t-test). A CHO cell line expressing
recombinant humanNOP receptors (positive control) expressed
1321 ± 60 fmol·mg1 protein (n = 4) of NOP receptors. More-
over, N/OFQ treatment of activatedHMC-1 cells induced a small
inhibition of the signalling messenger cAMP (19.3% at 300 nM
N/OFQ; Supporting Information Fig. SE2).A
C D
Figure 2
N/OFQ inhibits bronchial hyperreponsiveness. (A) In vivo experimental pro
post-OVA sensitization); (B) in vivo experimental protocol: N/OFQ administe
(C) representative image of N/OFQ (green) qualitative and quantitative expr
ment of ACh-induced lung resistance in an in vivo model (N/OFQ post-OVA
ACh-induced lung resistance in an in vivo model (N/OFQ pre-OVA sensitizat
Statistical comparisons by one-way or two-way ANOVA followed by appropr
1 μM is equivalent to 15 μg·kg1.
1292 British Journal of Pharmacology (2016) 173 1286–1301Overall, these data demonstrate that the N/OFQ-NOP
receptor system is not only present in human airways but may
also have a role in asthma as suggested by increased N/OFQ.
The N/OFQ-NOP receptor system may be positively involved
in airway pathophysiology; we, therefore, considered whether
the concentrationwas sufficiently increased to completely ame-
liorate inflammation in vivo and whether an additional exoge-
nous N/OFQ supplement is required to induce beneficial effects.Exogenous N/OFQ improves functional
parameters and reduces inflammation in
experimental allergic asthma
To investigate the impact of exogenous N/OFQ on allergic
asthma, N/OFQ was administered in mice prior to allergen
sensitization or during the challenge period to examine effects
on established airway inflammation (Figure 2A and B). Airways
of OVA-challenged mice showed increased N/OFQ expression
(Figure 2C), remarkably similar to that seen in human airways.
N/OFQ treatment, either pre-OVA or post-OVA sensitization,E
B
tocol: N/OFQ administered 30 min prior to OVA challenge (N/OFQ
red 30min prior to OVA-sensitization (N/OFQ pre-OVA sensitization);
ession in vivo by immunofluorescence, scale bars 20 μm; (D) measure-
sensitization) with AUC (inset, n = 6 mice); and (E) measurement of
ion) with AUC (inset), n = 4 mice. Data are expressed as mean ± SEM.
iate post hoc tests where relevant *P <0.05. N/OFQ administered at
N/OFQ-NOP system modulates airway immune response BJPreducedACh-induced bronchoconstriction. Importantly, N/OFQ
given duringOVAaerosol-challenge (postOVA-sensitization) ap-
peared to induce a greater degree of inhibition in ACh-induced
AHR when compared with N/OFQ treatment during OVA sensi-
tization (pre-OVA sensitization) (62.5% vs. 51%; Figure 2D and E).
BAL analysis showed that N/OFQ administration signifi-
cantly reduced total cell counts in OVA mice. Of note, OVA-
induced increase in eosinophils was markedly reduced by
N/OFQ in both protocols, while the effect on lymphocytes
was apparent only when N/OFQ was administered during
OVA challenge (Figure 3A and B). There was no significant effect
on neutrophils (Figure 3A and B) or alveolar macrophages (data
not shown). Histological evaluation revealed an increase in
peribronchial inflammatory infiltrates in the lungs of animals
sensitized and challenged with OVA, and this was markedly
reduced by N/OFQ (Figure 3C and D). Additionally, N/OFQ
treatments appeared to reduce peribronchial eosinophil infil-
tration in OVA-challenged mice (Figure 3E and F). Although
bronchial and peribronchial mast cell accumulation was not
observed, the total number of mast cells within the lung tissue
of OVA-sensitized and challenged mice increased. This was
lower in N/OFQ-treated groups (Figure 3G and H).
Because Th1 and Th2 cytokines play an important role in
allergic inflammation, to determine if N/OFQ affects inflam-
matory mediators in vivo, cytokine profile was analysed in
BAL. When N/OFQ was administered during OVA sensitization
and during the OVA challenge phase, the treatment significantly
reduced allergen-induced increases in IL-4, IL-5, IL-12 and IL-13
(Supporting Information Fig. SE3a–d; Figure 4A–D). Further ad-
ministration of N/OFQ during OVA challenge significantly po-
tentiated OVA-stimulated increase in BAL IL-10 levels and
reduced OVA-induced IL-17 (Figure 4E and F). No effect was ob-
served on IFN-γ levels (not shown). However, it had no effect on
IL-10 and IL-17 levels following administration during the OVA
sensitization phase (Supporting Information Fig. SE3e and f).
Finally, OVA-specific IgE in BAL fluid and plasma samples
were significantly reduced by N/OFQ (Figure 4G and H).
N/OFQ treatment had no effect on OVA-specific IgG levels
in either BAL fluid or plasma (Figure 4I and J). These observa-
tions suggest a Th2-selective immunomodulatory effect of
N/OFQ in vivo.N/OFQ inhibits agonist-induced human
airway smooth muscle cell contraction
Next, we determined whether the exposure to exogenous
N/OFQ affects the functional properties of human airway
structural cells. As an index of in vitro airway smooth muscle
contractility, carbachol induced a significant time-dependent
collagen gel contraction initiating at 30 min post-stimu-
lation with a maximum effect after 180 min. There was a
significant concentration and time-dependent inhibition of
carbachol-induced contractility following 24 h pre-treat-
ment with 3 and 300 nMN/OFQ (P< 0.05 following repeated
measures by two-way ANOVA). These inhibitory responses
were significant from 60 to 180 min post-agonist treatment
(Figure 5A–C). We observed a similar effect of N/OFQ on
bradykinin-induced gel contraction (Supporting Informa-
tion Fig. SE4). There was no significant difference between
the effect of N/OFQ on agonist-induced contraction of
healthy and asthmatic HASMs.N/OFQ inhibits migration of human mast cells
and eosinophils
Sputum from severe asthmatics containing 15–35 pg·mL1
(8–19 pM) N/OFQ induced a significant increase in EOL-1
and PBE migration. Addition of 30 or 300 nM exogenous
N/OFQ significantly inhibited these effects (Figure 6A and B;
Supporting Information Fig. SE5a and b).
Chemoattractants including SCF, CXCL10 and superna-
tants from HASM stimulated with 10 ng·mL1 of TNF-α
(HASM sn) induced an increase in HMC-1 migration (SCF: 2.5-
fold over control; CXCL10: 1.98-fold over control; HASM sn:
2.67-fold over control). SCF-induced HLMC migration (2.34-
fold over control) was inhibited by N/OFQ (Figure 6C;
Supporting Information Fig. SE5c). ECM-stimulated eosinophil
migration (2.33-fold over control) was also attenuated by
300 nM N/OFQ (Figure 6C; Supporting Information Fig. SE5d).
Furthermore, N/OFQ (300 nM) significantly inhibited SCF,
CXCL10 andHASMsn-stimulatedHMC-1migration (Figure 6C;
Supporting Information Fig. SE5e and f).N/OFQ inhibits the release of chemoattractants
that mediate human mast cell and eosinophil
migration
IL-8 and TNF-α play vital roles in the recruitment ofmast cells to
sites of inflammation (Nilsson et al., 1999; Olsson et al., 2004).
SCF-stimulated IL-8 release from HMC-1 cells was significantly
inhibited by N/OFQ (Figure 6D). However, there was no effect
on TNF-α release (Supporting Information Fig. SE6).
CCL11 and CCL26 are involved in the activation and
recruitment of PBEs (Garcia-Zepeda et al., 1996; White et al.,
1997). N/OFQ treatment demonstrated a trend towards
reduced (increased ΔCt). TNF-α-stimulated CCL11 mRNA ex-
pression in HASM (Figure 6E) and TNF-α-stimulated CCL11
release appear to be inhibited by N/OFQ (Figure 6F). N/OFQ
treatment appeared to reduce IL-13-stimulated CCL26mRNA
transcript and protein expression in HBEC (Figure 6G and H).N/OFQ promotes wound repair of human airway
structural cells but has no effect on cell
proliferation
Features of airway remodelling include epithelial cell damage
and mucus hypersecretion. Airway epithelial repair is regu-
lated through the proliferation, migration and differentiation
of cells adjoining the damaged area (Tam et al., 2011).
To test the effects of N/OFQ on the repair capacity of
bronchial epithelium, confluent monolayers of undifferenti-
ated healthy and asthmatic HBEC were scratch wounded in
the presence or absence of the peptide. Although a complete
wound closure (a combination of proliferation andmigration
or chemotaxis) was not achieved, N/OFQ appeared to pro-
mote wound repair of healthy HBECs and significantly in-
duced wound closure of asthmatic HBECs (Figure 7A and B);
the magnitude of the effect was larger in asthmatic HBECs.
Similarly, N/OFQ also promoted wound closing in HASM
cultures. Specifically, wound closure of non-asthmatic HASM
was promoted only by 300 nM N/OFQ, while asthmatic
HASM wound closure was markedly increased with 3, 30
and 300 nMN/OFQ (Figure 7C and D). There was a significantBritish Journal of Pharmacology (2016) 173 1286–1301 1293
Figure 3
N/OFQ inhibits inflammatory cell infiltration in vivo and recruitment of inflammatory cells within mouse airway tissues. (A) Total and differential
cell count in mouse BAL fluid in an in vivomodel (N/OFQ post-OVA sensitization, n = 6mice), (B) total and differential cell count in mouse BAL fluid
in an in vivo model (N/OFQ pre-OVA sensitization, n = 3 mice). (C) Representative image of HE staining in a N/OFQ post-OVA sensitized mouse
airways (n = 6 mice). Scale bars 50 μm. (D) Representative image of HE staining in a N/OFQ pre-OVA sensitization mouse airways (n = 3 mice).
Scale bars, 50 μm. (E) Modified HE staining showing the kinetics of eosinophilia in a N/OFQ post-OVA sensitization model (representative image,
n = 7 mice) within peribronchial tissue. Scale bars, 10 μ. (F) Modified HE staining showing the kinetics of eosinophilia in a N/OFQ pre-OVA sen-
sitization model (representative image, n = 4 mice) within peribronchial tissue, scale bars, 10 μm. (G) Representative image of mast cells detected
by toluidine blue staining, n = 7 mice. Scale bars, 20 μm. (H) Quantitative estimation of mast cells mm-2 of mice airway tissue in a N/OFQ pre-OVA
sensitization mouse airways (n = 4 mice). Data expressed as mean ± SEM and analysed by one-way ANOVA followed by appropriate post hoc tests
where relevant. *P <0.05.
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Figure 4
Administration of N/OFQ following sensitization and challenge with OVA regulates release of inflammatory mediators in vivo. (A) IL-4, (B) IL-5, (C)
IL-12, (D) IL-13, (E) IL-10 and (F) IL-17 cytokine levels in mouse BAL fluid obtained from different treatment groups, n = 5–9 mice. Data are
expressed as pg·mL1 (mean ± SEM). (G) Measurement of OVA-specific IgE in BAL fluid (n = 5 mice) and (H) in plasma (n = 10–12 mice). Data
are expressed as ng·mL1 (mean ± SEM). (I) Measurement of OVA-specific IgG levels in mouse BAL fluid and (J) in mouse plasma. Data are
expressed as U·mL1 (mean ± SEM). Statistical comparisons by one-way ANOVA followed by appropriate post hoc tests where relevant. *P <0.05.
N/OFQ-NOP system modulates airway immune response BJPtime (P < 0.05) and dose-dependent closure of HASM wound
(P < 0.05; repeated measures by two-way ANOVA).
Additionally, mitogen-induced proliferation of HASMs,
HMC-1 cells alone (Supporting Information Fig. SE7) or when
co-cultured with HASMs was not influenced by N/OFQ (data
not shown).
Finally, as the in vivo counterpart, the response of airway
epithelium to the exogenous N/OFQ was evaluated. In
animals sensitized and challenged with OVA, administration
of N/OFQ reduced by ~50% the extent of epithelial damage
(not shown) and decreased the fraction of mucin-labelled
epithelial cells (Figure 7E and F).Discussion
Using a combination of complementary in vitro human and
in vivomouse studies, we showed that AHR, eosinophil andmast
cell migration and inflammatory mediator release in the lungs
were dramatically inhibited by N/OFQ. This is the first studyto report a critical role for this system in asthma and describes
a novel agent with combined anti-hyperresponsiveness and
immunomodulatory properties.
There is emerging evidence suggesting a generalized
immunomodulatory role for the N/OFQ-NOP receptor
system (Miller and Fulford, 2007), and our data showed that
asthmatic sputum had significantly elevated levels of
N/OFQ. This may come from the increased eosinophil counts
as there was a correlation between increased eosinophils and
elevated N/OFQ. N/OFQ inhibited eosinophil and mast cell
migration and attenuated the release of inflammatory media-
tors that play key roles in their recruitment. Interestingly,
N/OFQ expression was found to be up-regulated in the lung
biopsies from asthmatic patients. In particular, N/OFQ was
increased in the sub-epithelial layer and extracellular matrix.
We also demonstrated significant NOP receptor expression in
human airway structural and inflammatory cells with
ppN/OFQ expression only in eosinophils. However, we did
not detect any significant increase in NOP receptor expres-
sion in asthma implying no disease signal. FunctionalBritish Journal of Pharmacology (2016) 173 1286–1301 1295
Figure 5
N/OFQ-NOP activation modulates agonist-induced HASM contraction. (A) Carbachol-induced time-dependent gel contraction (n = 7 HASM cells
from seven independent donors); *statistical comparisons between carbachol and control; #statistical comparisons between N/OFQ and carba-
chol. (B) AUC-carbachol response and (C) AUC-carbachol response normalized to control (expressed as 100%). Data are expressed as mean ±
SEM. Comparisons by one-way ANOVA followed by appropriate post hoc tests where relevant. *P <0.05; #P <0.05.
BJP S R Singh et al.in vitro studies showed that N/OFQ significantly inhibited
agonist-induced HASM-embedded gel contraction, and we
hypothesize that this could be an additional effect to its
anti-inflammatory role, a response that requires further
investigation.
Asthmatic sputumcontains several cytokines and chemokines
that regulate eosinophil migration including IL-5, IL-8, RANTES,
IgA and complexes of IL-8–IgA (Louis et al., 1997). The increase
in the levels of endogenous N/OFQ in sputum (~8–19 pM;
15–35 pg·mL1) of asthmatic patients was several orders of
magnitude lower than that required to exert beneficial effects
in vitro. We therefore suggest that additional exogenous N/OFQ
administration in the airways might present a new therapeutic
strategy for asthma. This hypothesis is supported by our observa-
tion that spiking sputum from severe asthmatics (with reported
high levels of endogenous N/OFQ) with additional N/OFQ (30
and 300 nM), which is over 2000-fold higher than concentrations
measured endogenously, significantly attenuated themigration of
eosinophils towards asthmatic sputum.
N/OFQ is a naturally occurring peptide and does not cross
the blood brain barrier (Lambert, 2008), and no significant
adverse effects were reported in a clinical trial evaluating the1296 British Journal of Pharmacology (2016) 173 1286–1301urodynamic effects of intravesical administration of 1 μM
N/OFQ in patients with neurogenic detrusor activity (Lazzeri
et al., 2003). Therefore, any systemic/local administration of
N/OFQ is unlikely to induce any unwanted central effects.
As a proof of concept, our in vivo experiments confirmed the
hypothesis that exogenous N/OFQ can ameliorate the course of
asthma. OVA sensitization followed by challenge has been
widely used as a model of airway inflammation although this
may not entirely reflect human asthma pathology. It does, how-
ever, retain many features of human allergic asthma including
Th2 cytokine production, goblet cell hyperplasia, mast cell de-
granulation, IgE production, AHR and airway remodelling
(Kumar and Foster, 2001; Gelfand, 2002; Kumar et al., 2008;
Han et al., 2013). We found a significant reduction of allergen-
increased levels of IL-4, IL-5, IL-12 and IL-13, Th2 cytokines
linked to inflammation (Brightling et al., 2002b). These observa-
tions were consistent with previous reports demonstrating
inhibition of IL-2 release and T-cell proliferation by N/OFQ
(Miller and Fulford, 2007; Easten et al., 2009). Surprisingly, we
did not observe any significant effect of N/OFQ on IFN-γ
production, that is the principal effector of Th1-mediated
inflammation and has a protective effect against Th2-driven
Figure 6
N/OFQ inhibits inflammatory cell migration by blocking mediator release in vitro. (A) Migration of EOL-1 cells (n = 8 replicates) and (B) PBEs
towards asthmatic sputum (n = PBEs from 7 independent donors). (C) Migration of mast cells and eosinophils through an 8 μm (pore-size)
transwell membrane (n = 5–7 independent donors). *Statistical comparisons with control, #statistical comparisons with relevant chemotactic
stimuli. (D) SCF-induced IL-8 release from HMC-1 cells (n = 7 replicates). (E) HASM CCL11 mRNA (n = 4 HASM cell samples from 4 independent
donors) expression. (F) CCL11 levels in HASM supernatants (n = 6 HASM cell samples from 6 independent donors). (G) HBEC CCL26 mRNA (n = 3
HBEC samples from 3 independent donors) expression. (H) CCL26 levels in HBEC supernatants (n = 3 HBEC samples from 3 independent donors).
Data expressed as mean ± SEM. Comparisons by one-way ANOVA followed by appropriate post hoc tests where relevant. *P <0.05; #P <0.05.
N/OFQ-NOP system modulates airway immune response BJPimmune responses (Teixeira et al., 2005). Additionally, N/OFQ
was able to inhibit levels of OVA-specific IgE in BAL fluid.
However, it failed to modulate OVA-specific IgG levels. These
observations suggest a Th2 selective immunomodulatory effect
of N/OFQ in vivo.
Of note, we administered N/OFQ either prior to or concur-
rent with OVA; this has important consequences for potential
treatment paradigms. The observation that N/OFQ has efficacy
in both models indicates that use in a clinical setting could
involve both prophylaxis and control of acute symptoms. These
data confirm and extend our recent study with the highly selec-
tive non-native NOP agonist UFP-112 (Sullo et al., 2013).
One of the characteristic features of airway remodelling is
epithelial cell damage. Abnormal epithelial shedding in
asthmatic patients with a variable degree of epithelial damage
has been observed (Liu et al., 2013). Repair of airway epithe-
lium is regulated through the proliferation, migration and
differentiation of cells adjoining the damaged area (Tam
et al., 2011). Glucocorticoids, one of the principal drug classes
used in asthma, play a key immunomodulatory role in airway
inflammation and provide a sustained repair potential for
mechanically injured human airway epithelial cells (Barnes,
2002; Wadsworth et al., 2006). However, studies have also
shown that steroids can adversely affect the repair process
by suppressing the early-stage migration and proliferation
of airway epithelial cells (Wadsworth et al., 2006; Liu et al.,2013). Therefore, to identify a role for N/OFQ in repair, we
explored the effect of this peptide on HBEC and HASM cell
wound healing. We observed a significant up-regulation in
wound repair that relates more to lung cell homeostasis than
immunomodulation. Importantly, this effect was predomi-
nant in cells from asthmatic airways. Additionally, N/OFQ
reduced mucus production in vivo.
An important issue in chronic treatments is GPCR signal-
ling desensitization due to persistent ligand binding at high
doses. NOP receptor signalling is regulated by the process of
homologous desensitization (Donica et al., 2013). Several fac-
tors are known to regulate this process including NOP
receptor density, dose and duration of exposure, peptide
and non-peptide agonists. Acute exposure to its agonist
N/OFQ does not induce NOP receptor down-regulation
(Dautzenberg et al., 2001). However, long-term exposure to
N/OFQ differentially induces down-regulation in a time-
dependent manner (Hashimoto et al., 2002). Our in vitro as-
says demonstrated beneficial effects of N/OFQ at 3, 30 and
300 nM following administration of a single-dose for either
4 or 24 h. It would therefore be interesting to investigate
whether this N/OFQ administration regimen would result in
desensitization of the NOP receptor. Another interesting ob-
servation would be to determine whether this would activate
any compensatory mechanism(s) to maintain NOP receptor
expression.British Journal of Pharmacology (2016) 173 1286–1301 1297
Figure 7
N/OFQ-NOP activation promotes wound repair of human airway structural cells and inhibits recruitment of mucin-labelled cells in vivo. (A) Wound
repair of undifferentiated healthy (n = 3 HBEC samples from 3 independent donors) and (B) asthmatic HBEC (n = 5 HBEC samples from 5 indepen-
dent donors). (C) Wound repair of non-asthmatic (n = 5 HASM cell samples from 5 independent donors) and (D) asthmatic HASMs (n = 5 HASM
cell samples from 5 independent donors). (E) Mucin-labelled cells (green) in airway epithelium following administration of N/OFQ post-OVA sen-
sitization (n = airway tissue from 7 mice), scale bars 20 μm. (F) Mucin-labelled cells (green) in airway epithelium following administration of N/
OFQ prior to OVA sensitization (n = airway tissue from 4 mice). Data are expressed as mean ± SEM. Comparisons by one-way ANOVA followed
by appropriate post hoc tests where relevant. *P<0.05; #P <0.05. In panels (C and D), there was a significant time (P <0.05) and dose-dependent
closure of HASM wound (P <0.05; repeated measures by two-way ANOVA).
BJP S R Singh et al.The main limitations of our study relate to lack of antag-
onist data and mechanistic information. Use of the antago-
nist UFP-101 in several other studies is questionable as it
may have partial agonist activity (Mahmoud et al., 2010)
making interpretation problematic. Mechanistic details
would be useful in particular the role of downstream signal-
ling events in the N/OFQ-NOP system including calcium
channel modulation, activation of PKC, MAPK, extracellular
signal-regulated kinase 1/2 and Rho kinases; this would need
further investigation (Baiula et al., 2013). Despite these limi-
tations, key strengths of our findings include consistency
of the observations between human data and an animal
model and the magnitude of the effects observed. The
anti-inflammatory effects upon eosinophilic inflammation
in the in vivo model are larger than typically observed
with corticosteroids (Lee et al., 2008) and are similar to
IL-5 neutralization (Leckie et al., 2000). The magnitude
of the effect upon cell migration was also larger than1298 British Journal of Pharmacology (2016) 173 1286–1301observed in response to corticosteroids or any anti-
inflammatory therapy we have investigated (Wardlaw
et al., 2000). The effect upon airway hyperresponsiveness
in vivo was similar to those described for anti-IL-13 and
anti-IL-17 (Yang et al., 2004; Kinyanjui et al., 2013), but
the effect upon inhibiting in vitro agonist-induced airway
smooth muscle contraction was the largest.
Clinical translation of this data set is a critical future
development, but clearly, there are ‘non-therapeutic’ is-
sues with N/OFQ as it is a natural product already in the
public domain. Supraspinal NOP receptor activation has
the potential to produce hyperalgesic/antiopioid effects
(Schröder et al., 2014), but our observations in human
and mouse suggest the main effects on airways are purely
peripheral. A simple clinical trial of nebulized N/OFQ
both as a prophylactic and during an exacerbation of
asthma is clearly warranted. The use of a nebulized formu-
lation would reduce total body dosing, negate the
N/OFQ-NOP system modulates airway immune response BJPlikelihood of central spread and offer the advantage of a
single entity combining anti-hyperresponsiveness and
immunomodulatory actions.
Our data suggest that endogenous N/OFQ is elevated in
asthma, but its concentrations are too low to substantially
modulate the immune system and AHR indicating that
supplementation with exogenous N/OFQ is needed.
In conclusion, we have identified an important and an
innovative role for N/OFQ in counteracting non-neurogenic air-
way inflammatory responses and airway hyperresponsiveness.
This combination of beneficial effects is rarely observed and
supports our assertion that this opens a completely new poten-
tial target/strategy in the treatment of asthma.Acknowledgements
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Figure S1 N/OFQ levels in asthmatic sputum do not corre-
late with FEV1/FVC ratio. Spearman correlation between spu-
tum N/OFQ and FEV1/FVC ratio.
Figure S2NOP receptors on HMC-1 cells are coupled to inhi-
bition of cAMP production. Measurement of cAMP formation
in HMC-1 cells (n=7 independent experiments) following
forskolin stimulation (1 M) significantly inhibited (P< 0.05)
forskolin-stimulated increase in cAMP formation. Data expressed
as fold change over basal and was analysed by one-way ANOVA
with Bonferroni’s multiple comparison test. *P< 0.05.
Figure S3 Administration of N/OFQ during OVA-sensitisation
regulates release of inflammatory mediators in vivo. (a) IL-4, (b)
IL-5, (c) IL-12, (d) IL-13, (e) IL-10 and (f) IL-17 cytokine levels in
mouse BAL fluid obtained from different treatment groups (N/
OFQ pre and post OVA-sensitization), n=3. Data expressed as
pg/ml (mean±SEM).
Figure S4 N/OFQ-NOP activation modulates agonist-induced
HASM contraction. (a) Bradykinin-induced time-dependant gel
contraction (n=HASM cells from 7 independent donors) and (b)
AUC-bradykinin response. Data expressed as mean±SEM. Com-
parisons made by two-way ANOVA. Contraction data are a com-
bination of cells harvested from healthy and asthmatic patients.
Figure S5 N/OFQ inhibits inflammatory cell migration in vitro.
(a) Migration of EOL-1 cells (n=8 replicates) and (b) PBEs towards
asthmatic sputum (n=PBEs from 7 independant donors), (c) Mi-
gration of HLMC towards SCF (n=7 independant donors), (d)Mi-
grationof PBEs (n=PBEs from6 independent donors) to epithelial
conditioned media, (e) Migration of HMC-1 to SCF and CXCL10
(n=5 replicates), (f) Migration of HMC-1 to ASM supernatants
(n=8 replicates). Data expressed as mean ± SEM. Comparisons
by one-way ANOVA. *P< 0.05.
Figure S6 N/OFQ had no effect on TNF-α release from HMC-1
cells. SCF-induced TNF-α release from HMC-1 cells (n=6 inde-
pendent experiments) was not modulated by N/OFQ pre-treat-
ment. Data expressed as pg/ml (mean ± SEM) and analysed by
paired t-test.
FigureS7N/OFQdoes notmodulatemitogen-induced prolifer-
ation of HASMs and HMC-1 cells. (a) [3H] thymidine incorpora-
tion was measured in HASM cultures stimulated with
plateletderived growth factor (PDGF-AB, 20 ng/ml) for 24 h in
the presence or absence of N/OFQ expressed as fold change,
(b) MTS colorimetric assay was performed to detect HMC-1 cell
viability and proliferation following stimulation with stem cell
factor (SCF, 10 ng/ml) for 24h in the presence or absence of N/
OFQ expressed as fold change, (c) [3H] thymidine incorporation
was measured in HASM cultures stimulated with platelet-de-
rived growth factor (PDGF-AB, 20 ng/ml) for 24 h in the pres-
ence or absence of N/OFQ expressed as actual counts, (d) MTS
colorimetric assay was performed to detect HMC-1 cell viability
and proliferation following stimulation with stem cell factor
(SCF, 10 ng/ml) for 24 h in the presence or absence of N/OFQ
expressed as actual counts. All data represent mean ± SEM
(n=6 independent experiments). Comparisons made by one-
way ANOVA. *P< 0.05.British Journal of Pharmacology (2016) 173 1286–1301 1301
